modelInosine
Extends from Pharmacolibrary.Drugs.ATC.G.G01AX02.
Information
| name: | Inosine | |
| ATC code: | G01AX02 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 0.6 | L |
| clearance: | 120 | mL/min |
| other parameters in model implementation | ||
Inosine is a purine nucleoside formed by the deamination of adenosine. It has been used as a medication for various conditions, such as immunomodulation or neuroprotection, but it is not widely approved or in common use today. Its utility in clinical practice is limited and not supported by major regulatory agencies.
Pharmacokinetics
No published pharmacokinetic data are available for inosine in humans; the following parameters are estimates based on its structural similarity to adenosine and other nucleosides, as well as general pharmacokinetic principles.
References
Staatz, CE, & Tett, SE (2007). Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clinical pharmacokinetics 46(1) 13–58. DOI:10.2165/00003088-200746010-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17201457
Li, H, et al., & McCune, JS (2014). Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20(8) 1121–1129. DOI:10.1016/j.bbmt.2014.03.032 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24727337
McHutchison, JG, et al., & Alam, J (2005). A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antiviral therapy 10(5) 635–643. PUBMED:https://pubmed.ncbi.nlm.nih.gov/16152757
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)